Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication. by Mead, A, Gale, R, Kottaridis, P, Matsuda, S, Khwaja, A, Linch, D

The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial by Burnett, AK, Gupta, ED, Knapper, S, Khwaja, A, Sweeney, M, Kjeldsen, L, Hawkins, T, Betteridge, SE, Cahalin, P, Clark, RE, Hills, RK, Russell, NH

A G1‐like state allows HIV‐1 to bypass SAMHD1 restriction in macrophages by Mlcochova, P, Sutherland, KA, Watters, SA, Bertoli, C, de Bruin, RA, Rehwinkel, J, Neil, SJ, Lenzi, GM, Kim, B, Khwaja, A, Gage, MC, Georgiou, C, Chittka, A, Yona, S, Noursadeghi, M, Towers, GJ, Gupta, RK

Molecular MRD status and outcome after transplantation in NPM1-mutated AML by Dillon, R, Hills, R, Freeman, S, Potter, N, Jovanovic, J, Ivey, A, Kanda, AS, Runglall, M, Foot, N, Valganon, M, Khwaja, A, Cavenagh, J, Smith, M, Ommen, HB, Overgaard, UM, Dennis, M, Knapper, S, Kaur, H, Taussig, D, Mehta, P, Raj, K, Novitzky-Basso, I, Nikolousis, E, Danby, R, Krishnamurthy, P, Hill, K, Finnegan, D, Alimam, S, Hurst, E, Johnson, P, Khan, A, Salim, R, Craddock, C, Spearing, R, Gilkes, A, Gale, R, Burnett, A, Russell, NH, Grimwade, D